

1 **Racial/ethnic differences in pre-pregnancy conditions and**  
2 **adverse maternal outcomes in the nuMoM2b cohort: a**  
3 **population-based cohort study**

4  
5 **Short Title:** *Pre-Pregnancy Conditions and Adverse Maternal Outcomes*  
6

7 Meghan E. MEREDITH, BS

8 H. Milton Stewart School of Industrial and Systems Engineering

9 Georgia Institute of Technology

10 755 Ferst Drive, NW Atlanta, GA 30332

11  
12 Lauren N. STEIMLE\*, PhD

13 H. Milton Stewart School of Industrial and Systems Engineering

14 Georgia Institute of Technology

15 755 Ferst Drive, NW Atlanta, GA 30332

16  
17 Kaitlyn K. STANHOPE, PhD

18 Department of Gynecology & Obstetrics

19 Emory University

20 100 Woodruff Circle, Atlanta, GA 30322 USA

21  
22 Marissa H. PLATNER, MD

23 Department of Gynecology & Obstetrics

24 Emory University

25 100 Woodruff Circle, Atlanta, GA 30322 USA

26  
27 Sheree L. BOULET, DrPH

28 Department of Gynecology & Obstetrics

29 Emory University

30 100 Woodruff Circle, Atlanta, GA 30322 USA

31  
32 \* Corresponding author: Lauren N. Steimle, [steimle@gatech.edu](mailto:steimle@gatech.edu)

## 33 **Abstract**

34 **Objective** To: (1) determine how pre-existing conditions contribute to racial disparities  
35 in adverse maternal outcomes; and (2) incorporate these conditions into models to  
36 improve risk prediction for racial minority subgroups.

37 **Design** Secondary data analysis of a population-based cohort study.

38 **Setting** Academic healthcare institutions in the United States.

39 **Population** A cohort of 8,729 women included in the "Nulliparous Pregnancy  
40 Outcomes Study: Monitoring Mothers-to-be (nuMoM2b)".

41 **Methods** Poisson regression to estimate adjusted risk ratios, and mediation analysis  
42 to evaluate the contribution of multimorbidity to racial/ethnic disparities. Area under the  
43 receiver operating characteristic curve (AUC) to evaluate model performance.

44 **Main Outcome Measures** Incidence of severe preeclampsia, postpartum  
45 readmission, and blood transfusion.

46 **Results** In the nuMoM2b cohort (n=8729), accounting for pre-existing conditions  
47 attenuated the association between non-Hispanic Black race/ethnicity and risk of severe  
48 preeclampsia. Cardiovascular and kidney conditions were associated with risk for  
49 severe preeclampsia among all women (aRR, 1.77; CI, 1.61-1.96, and aRR, 1.27; CI,  
50 1.03-1.56 respectively). The mediation analysis results were not statistically significant;  
51 however, cardiovascular conditions explained 36.6% of the association between severe  
52 preeclampsia and non-Hispanic Black race/ethnicity (p=0.07). The addition of pre-  
53 pregnancy conditions increased model performance for the prediction of blood  
54 transfusion and severe preeclampsia.

55 **Conclusions** Pre-existing conditions may explain some of the association between  
56 severe preeclampsia and non-Hispanic Black race/ethnicity. Specific pre-pregnancy  
57 conditions were associated with adverse maternal outcomes and the incorporation of  
58 comorbidities improved the performance of most risk prediction models.

59 **Funding** Research reported in this publication was supported in part by Imagine,  
60 Innovate and Impact (I<sup>3</sup>) from the Emory School of Medicine, Georgia Tech, and through  
61 the Georgia CTSA NIH award (UL1-TR002378) and by the National Science Foundation  
62 under grant number DGE-2039655 (Meredith); any opinions, findings, and conclusions  
63 or recommendations expressed in this material are those of the authors and do not  
64 necessarily reflect the views of the National Science Foundation.

65 **Keywords** Maternal health, Pregnancy Complications, Maternal morbidity, Risk  
66 Assessment, Multimorbidity, Comorbidity, Chronic Conditions, Health Disparities

## 67 Introduction

68 The global maternal mortality rate has stalled after improving between 2000 and 2015.<sup>1</sup>  
69 The United States' maternal mortality rate, 23.8 per 100,000 live births, has worsened  
70 over the past 20 years,<sup>2,3</sup> and there are staggering racial and ethnic disparities in  
71 maternal mortality.<sup>4</sup> In the United States, compared with non-Hispanic white individuals,  
72 non-Hispanic Black individuals have 3 to 4 times the risk of dying during childbirth.<sup>5</sup> An  
73 estimated 80% of pregnancy-related deaths are considered preventable,<sup>6</sup> and  
74 individuals with adverse maternal outcomes have similar preventable factors including  
75 provider failure to identify high-risk status and inappropriate management.<sup>7</sup> Two  
76 potential targets for addressing pregnancy-related mortality and morbidity are  
77 improvements in chronic condition prevention before and during pregnancy and better  
78 prediction models for adverse outcomes that may disproportionately affect racial and  
79 ethnic minority individuals.

80  
81 Chronic conditions are associated with a higher risk of adverse maternal outcomes.  
82 Deliveries among racial and ethnic minorities, compared with non-Hispanic white  
83 individuals, experience significantly higher rates of maternal morbidity and also have a  
84 higher prevalence of chronic conditions.<sup>8</sup> Pregnant individuals with multiple co-occurring  
85 conditions, or *multimorbidity*, have higher rates of severe maternal morbidity and  
86 postpartum readmission.<sup>9</sup> While multimorbidity affects a substantial and likely growing  
87 proportion of the global adult population,<sup>10</sup> obstetric research and practice remain  
88 largely focused on the impact of single conditions on maternal outcomes,<sup>11</sup> apart from a  
89 few studies using administrative data,<sup>12,13</sup> and those creating comorbidity-based risk  
90 screening tools.<sup>14-16</sup> When multimorbidity is accounted for, it is typically represented as  
91 a binary indication of each condition or an indicator of the number of conditions, but  
92 these representations do not consider the types of co-occurring conditions (e.g.  
93 hematological and cardiovascular), which may be more relevant for clinical  
94 management.

95  
96 In this study, we investigate the impact of pre-pregnancy conditions and their combined  
97 effects on adverse maternal outcomes and whether these effects mediate the

98 relationship between racial disparities and adverse maternal outcomes in a cohort of  
99 nulliparous individuals in the United States. A better understanding of which conditions  
100 and combinations thereof drive increased maternal risk could inform the development of  
101 new clinical care standards for multimorbid pregnant people and potentially improve the  
102 ability to risk-stratify pregnant people early in pregnancy.

103

## 104 **Methods**

### 105 **Study Population**

106 We conducted a secondary analysis of data from the nuMoM2b prospective cohort  
107 study of nulliparous women.<sup>17,18</sup> The study recruited women from hospitals affiliated with  
108 eight clinical centers and collected data on each participant over the course of four  
109 study visits via in-clinic interviews, self-administered questionnaires, clinical  
110 measurements, and chart abstractions. The cohort included 9,289 women who  
111 consented to the release of their data.

112

### 113 **Data Preparation**

114 For this secondary data analysis, we chose to exclude women who delivered at  
115 gestational age < 22 weeks or > 43 weeks and those with terminations and unknown  
116 outcomes. We also excluded women with missing race/ethnicity and pre-pregnancy  
117 conditions data. To address missing data among confounders, we created 5 imputed  
118 datasets using multivariate imputation by chained equations (MICE).<sup>19</sup> Please see  
119 Appendix A for more details about the exclusion protocol and Appendix B.1 for more  
120 details about the data structure and preparation.

121

### 122 *Main Outcome Measures*

123 The primary outcomes of this study were severe preeclampsia, blood transfusion, and  
124 postpartum readmission (up to 14 days). These outcomes were selected because they  
125 are strongly associated with maternal mortality and morbidity,<sup>20,21</sup> and they have high  
126 quality measurements in the nuMoM2b dataset. Appendix B.2 provides details about the  
127 definitions and collection of the primary outcomes in the nuMoM2b study.

128

129 We fit prediction models to each of these outcomes individually to preserve the  
130 interpretability of model results and compared results across each outcome.

131

### 132 *Pre-Pregnancy Conditions*

133 Pre-pregnancy conditions were collected by the nuMoM2b study team at each of the  
134 first three visits through an in-person interview with the participant, who indicated the  
135 presence of each condition at any time throughout their life. The nuMoM2b study team  
136 reconciled this data with chart abstraction to finalize the indication of pre-pregnancy  
137 conditions.

138

139 The nuMoM2b study team collected 41 pre-pregnancy conditions, and we categorized  
140 them into 12 condition types according to the framework of Tang et al.<sup>22</sup> (Appendix  
141 Table S3). We grouped the pre-pregnancy conditions based on similarities in  
142 treatments, clinical manifestation, or organization in the health care system. For  
143 example, we grouped cervical dysplasia, fibroids, and PCOS under the condition type  
144 “Gynecological” because they are conditions that affect the function of female  
145 reproductive organs and are treated by the same gynecologist specialty branch. The  
146 condition types included: Autoimmune, Cardiovascular, Endocrine, Gastrointestinal,  
147 Gynecological, Hematologic, Kidney, Lung, Mental, and Neurological. This classification  
148 was developed and validated by three of our authors (KS, SB, MP) with extensive  
149 medical and specifically obstetric knowledge.

150

151 Our analysis considered pairs of co-occurring pre-pregnancy condition types. For  
152 example, consider a patient with the following three pre-pregnancy conditions: anemia  
153 (hematologic), hypertension (cardiovascular), and migraine headaches (neurological).  
154 This patient was indicated to have the following co-occurring condition types:  
155 hematologic & cardiovascular, cardiovascular & hematologic, and hematologic &  
156 neurological.

157

158 *Confounders*

159 We adjusted for confounding factors including maternal age, insurance, body mass  
160 index (BMI), and sociodemographic information including income and education. Each  
161 of these factors were collected during Visit 1, which occurred between gestational age 6  
162 and 14 weeks.

163

164 **Statistical Analysis**

165 We used Poisson regression models with robust standard errors to analyze the  
166 associations between pre-pregnancy condition types, self-reported race/ethnicity, and  
167 adverse maternal outcomes with the results reported as crude and adjusted risk ratios  
168 (RRs) and 95% confidence intervals (CIs). We used a class-weighting method which  
169 gives a higher priority to correctly classifying the subgroup of women who experienced  
170 an adverse maternal outcome (see Appendix B.3).

171

172 Potential mediators were selected for each adverse maternal outcome in a stepwise  
173 process to avoid multicollinearity. Each adverse maternal outcome was regressed by  
174 race/ethnicity, confounders, and all potential mediators (all pre-pregnancy condition  
175 types and all their combined effects) (hereafter referred to as the “Outcome Model”).  
176 Only condition types and combined effects reaching statistical significance ( $p$ -value  $\leq$   
177 0.05) in this model were included in further analysis. Additionally, only combined effects  
178 with at least 1% prevalence in the dataset were considered. Next, we used a model-  
179 building approach starting with a standard individual-level Poisson model (Model 1,  
180 crude), followed by a Poisson model that adjusted for confounders (Model 2, adjusted).  
181 We additionally controlled for significant pre-pregnancy condition types (Model 3), and  
182 finally, we additionally controlled for significant combined effects between co-occurring  
183 pre-pregnancy condition types (Model 4).

184

185 Next, we sought to determine if pre-pregnancy condition types and their combined  
186 effects contributed to the racial disparities in adverse maternal outcomes using  
187 mediation analysis. To analyze mediation, the potential mediator condition types and  
188 their combined effects were individually regressed by race/ethnicity and adjusted for

189 confounders (“Mediator Model”). The Outcome and Mediator models were combined to  
190 compute the mediation proportion, which estimates the proportion of the risk factor’s  
191 impact (race/ethnicity) on the outcome that is attributable to the mediator (pre-  
192 pregnancy condition type or combined effect).<sup>23</sup> This analysis was conducted for each  
193 adverse maternal outcome and results were averaged across the five imputed datasets.

194

## 195 Performance Analysis

196 Finally, we analyzed the performance of our prediction models (Model 1, Model 2,  
197 Model 3, and Model 4) to understand which pre-pregnancy patient characteristics  
198 accurately classified adverse maternal outcomes. The performance of each model was  
199 evaluated for each racial/ethnic subgroup using the average area under the ROC curve  
200 (AUC) across 10-fold cross-validation and across the five imputed datasets.

201

202 We used R, version 4.2.1, for all analysis, *caret* in R to train and test our prediction  
203 models and *mediate* in R to conduct mediation analysis. We use a p-value threshold of  
204 0.05 for statistical significance.

205

## 206 Results

207 After exclusions, the final study population included 8729 women (Table 1). Of those,  
208 61.0% (n=5322) identified as non-Hispanic white, 13.1% (n=1145) non-Hispanic Black,  
209 17.0% (n=1487) Hispanic, 3.9% (n = 342) Asian, 4.0% (n=348) multiracial, and 1.0%  
210 (n=85) “Other”. The non-Hispanic Black subgroup had the youngest average age (23.3  
211  $\pm$  5.3) and the largest average BMI (29.1  $\pm$  8.2). In total, the study population included  
212 157 cases (1.8%) of blood transfusion, 154 cases (1.8%) of postpartum readmission,  
213 and 318 cases (3.6%) of severe preeclampsia. The incidence of these adverse maternal  
214 outcomes varied by race and ethnicity (Table Appendix S2). The incidence of blood  
215 transfusion and severe preeclampsia was highest in non-Hispanic Black women and the  
216 incidence of all adverse maternal outcomes was lowest in Asian women.

217



218 The most common pre-pregnancy conditions were mental health conditions (14.4%,  
219 n=1261), hematologic conditions (13.8%, n=1206), neurological conditions (13.0%,  
220 n=1136), and lung conditions (12.5%, n=1091) (Table Appendix S4). Non-Hispanic  
221 Black women experienced the highest rates of lung and hematologic conditions,  
222 Hispanic women experienced the highest rates of kidney conditions, and multiracial  
223 women experienced the highest rates of cardiovascular conditions. Non-Hispanic white  
224 women experienced the highest rates of neurological, gastrointestinal, and mental  
225 health conditions.

226  
227 Of all women, 22.8% (n=1989) had co-occurring pre-pregnancy conditions, i.e., 2 or  
228 more conditions. Non-Hispanic white women had the highest rates of co-occurring pre-  
229 pregnancy conditions (24.9%, n=1327), followed by multiracial women (22.7%, n=79),  
230 and Non-Hispanic Black women (20.0%, n=229). The most common co-occurring pre-  
231 pregnancy conditions were Mental & Neurological (3.7%, n=322), Lung & Neurological  
232 (2.8%, n=248), and Hematologic & Lung (2.5%, n=216) (Table Appendix S5). Among  
233 non-Hispanic white women, the most common co-occurring pre-pregnancy conditions  
234 were Mental & Neurological (4.7%, n=248), Lung & Neurological (2.9%, n=153), and  
235 Hematologic & Lung (2.1%, n=111). Among non-Hispanic Black women, the most  
236 common co-occurring pre-pregnancy conditions were Hematologic & Lung (4.4%, n=50)  
237 and Cardiovascular & Hematologic (3.4%, n=39).

238  
239 Compared with non-Hispanic white women, the unadjusted risk of blood transfusion and  
240 severe preeclampsia was higher in non-Hispanic Black women. Statistical adjustment  
241 for age, sociodemographic information, insurance, and BMI eliminated the elevated risk  
242 of blood transfusion in non-Hispanic Black and Hispanic women and eliminated the  
243 elevated risk of severe preeclampsia for multiracial women. Statistical adjustment  
244 attenuated but did not eliminate the elevated risk of severe preeclampsia in non-  
245 Hispanic Black women. The adjusted relative risk (aRR) of severe preeclampsia was  
246 higher in non-Hispanic Black (aRR, 1.22; CI, 1.06-1.41) compared to non-Hispanic  
247 white women (Table 4).

248

249 After adjusting for confounders, we controlled for pre-pregnancy condition types (Model  
250 3) and their combined effects (Model 4). Controlling for pre-pregnancy condition types  
251 for the outcome of severe preeclampsia attenuated the risk of severe preeclampsia in  
252 non-Hispanic Black women (aRR 1.15, CI, 0.99-1.34) (Table 6).

253  
254 Pre-pregnancy condition types were associated with adverse maternal outcomes (see  
255 Tables 2-4). Autoimmune conditions significantly increased the risk for blood transfusion  
256 (aRR, 1.36; CI, 1.04-1.78) and postpartum readmission (aRR, 1.55; CI, 1.22-1.97).  
257 Hematologic conditions were associated with a significantly increased risk for blood  
258 transfusion (aRR, 1.42; CI, 1.23-1.64). Cardiovascular and kidney conditions were  
259 associated with a significantly increased risk for severe preeclampsia (aRR, 1.77; CI,  
260 1.61-1.96, and aRR, 1.27; CI, 1.03-1.56 respectively). Accounting for combined effects  
261 did not significantly impact effect estimates.

262  
263 Mediation analysis was conducted on all statistically significant condition types and  
264 combined effects for each adverse maternal outcome. There were no significant results  
265 at p-value < 0.05; however, cardiovascular conditions accounted for 36.6% of the  
266 association between non-Hispanic Black race/ethnicity and severe preeclampsia at p-  
267 value 0.07.

268  
269 Finally, we compared the performance metrics, specifically the area under the receiver  
270 operating characteristics curve (AUC), of models with different feature sets to determine  
271 the value of different maternal characteristics in predicting the risk of experiencing each  
272 of the adverse maternal outcomes (Table Appendix S6). We found gains in overall AUC  
273 with the addition of condition types for the prediction of blood transfusion and severe  
274 preeclampsia (AUC, 0.55 to 0.59, 0.61 to 0.65, respectively). We computed AUC for  
275 each racial and ethnic subgroup to understand how the models performed across the  
276 subgroups. AUC varies significantly by race for each adverse maternal outcome. Model  
277 3, which includes race, confounders, and condition types as features, has an AUC  
278 range of 0.50-0.67 for blood transfusion, 0.45-0.63 for postpartum readmission, and

279 0.49-0.70 for severe preeclampsia. The largest improvement in AUC from adding  
280 condition was in predicting blood transfusion in Multiracial women, from 0.49 to 0.67.

## 281 **Discussion**

### 282 **Main Findings**

283 Our findings suggest accounting for pre-pregnancy condition types explained some of  
284 the association between non-Hispanic Black race/ethnicity and severe preeclampsia.  
285 We found that including pre-pregnancy condition types improved diagnostic ability  
286 (AUC) in predictive models for blood transfusion and severe preeclampsia, both for the  
287 overall cohort and for most individual racial and ethnic groups. These results highlight  
288 the potential for risk prediction using pre-pregnancy conditions in a diverse, but low-risk  
289 population.

290

291 Consistent with previous studies,<sup>5,8,24–26</sup> we found that identification as a minority race  
292 was associated with a higher risk of adverse maternal outcomes among a cohort of  
293 nulliparous individuals. Adding to some studies that have examined the impact of  
294 specific co-occurring condition combined effects,<sup>27,28</sup> our study focused on exploring all  
295 potential pre-pregnancy condition type combined effects to understand their association  
296 with adverse maternal outcomes (specifically severe preeclampsia, postpartum  
297 readmission, and blood transfusion) and quantified the value of including combined  
298 effects in predictive models. No pre-pregnancy condition combined effects were  
299 significantly associated with adverse maternal outcomes.

300

301 We also quantified the association between individual pre-pregnancy condition type and  
302 adverse maternal outcomes. Each adverse maternal outcome was associated with  
303 different pre-pregnancy condition types, except the autoimmune condition type, which  
304 was associated with increased risk for both blood transfusion and postpartum  
305 readmission. It is well known that pregnancy is associated with changes in the maternal  
306 immune system, and specifically the postpartum period is associated with autoimmune  
307 disease flares.<sup>29</sup>

308

309 Our work adds to previous studies on the use of prediction models to predict various  
310 adverse outcomes, which have ranged from using symptoms and signs,<sup>14,16</sup> laboratory  
311 tests and biomarkers,<sup>30,31</sup> and demographics and medical history.<sup>32,33</sup> With the inclusion  
312 of pre-pregnancy condition types, our model yields an AUC of 0.65 for predicting severe  
313 preeclampsia, which is comparable to the AUC of previously published obstetric  
314 comorbidity indices predicting SMM, which included severe preeclampsia (Bateman, et  
315 al.<sup>15</sup>: AUC, 0.65 and Easter, et al.<sup>14</sup> : AUC, 0.70 as reported by Leonard et al.<sup>34</sup>). The  
316 prediction models for blood transfusion and severe preeclampsia improved with the  
317 addition of pre-pregnancy condition types; however, the model for postpartum  
318 readmission did not improve.

319

## 320 **Interpretation**

321 Understanding the potential reasons for adverse maternal outcomes is an important  
322 pathway to understanding and reducing racial and ethnic disparities and high rates of  
323 maternal morbidity and mortality.

324

325 Our findings suggest that the presence of pre-pregnancy conditions and confounders  
326 may explain some of the observed association between non-Hispanic Black  
327 race/ethnicity and severe preeclampsia. In a prior study, Black race was associated with  
328 increased odds of pregnancy-induced hypertension after adjustment for preexisting  
329 conditions and demographic factors.<sup>35</sup> However, our study adjusts for a different set of  
330 preexisting conditions. The prevention and management of these pre-existing  
331 conditions, specifically cardiovascular conditions, before, during, and between  
332 pregnancies could be an important consideration to decrease racial and ethnic  
333 disparities in adverse maternal outcomes. Although the nuMoM2b cohort study  
334 collected data on a wide range of pre-pregnancy conditions, we could not explain a  
335 large proportion of the disparities in maternal morbidity in this cohort. Future work may  
336 benefit from the inclusion of additional data such as the severity and management of  
337 morbidity and multimorbidity during the preconception, interconception, and postpartum  
338 periods to determine whether differential management reduces the observed disparities.

339

340 Our work suggests that information about pre-pregnancy conditions can be useful in  
341 improving the ability to risk-stratify individuals. The use of predictive modeling may be  
342 useful to further explore the complex relationships of co-occurring conditions. However,  
343 more research is necessary to inform best clinical practice for the use of predictive  
344 models with a focus on mitigating unintended consequences and preventing the  
345 exacerbation of disparities.<sup>36</sup>

346

### 347 **Strengths and Limitations**

348 Our study has several strengths. Using a large and comprehensive dataset, we  
349 evaluated the association between race and ethnicity, pre-pregnancy conditions, and  
350 adverse maternal outcomes in a cohort of nulliparous women in the United States. This  
351 dataset contains thoroughly collected data that goes beyond a typical electronic health  
352 record including health history and conditions, demographics, and survey  
353 questionnaires. Our condition type groupings allowed for larger sample sizes of  
354 conditions and more accurate estimates of risk ratios. In addition, the use of feature  
355 selection algorithms allowed for the exploration of combined effects to improve model  
356 performance for predicting adverse maternal outcomes.

357

358 Our study has several important limitations. First, the analysis was limited to the data  
359 collected in the nuMoM2b dataset, which only includes nulliparous, predominantly non-  
360 Hispanic white women who received regular prenatal care at academic medical centers  
361 and began care before 13 weeks and 6 days gestation; thus, our findings may not be  
362 generalizable to different birthing populations. Second, the nuMoM2b dataset also does  
363 not indicate the severity or long-term treatment status of pre-pregnancy conditions.  
364 Third, our dataset only collected data up to 14 days postpartum, although many  
365 postpartum readmissions occur after this timespan.<sup>37</sup> Finally, adverse pregnancy  
366 outcomes are rare and occur infrequently in the nuMoM2b dataset, particularly as we  
367 stratified by racial subgroups and by multimorbidity. A larger sample size may be able to  
368 identify more statistically significant associations between pre-pregnancy conditions and  
369 maternal outcomes that occur infrequently.

## 370 **Conclusion**

371 In addition to describing associations between race and ethnicity, pre-pregnancy  
372 condition types and their combined effects, and adverse maternal outcomes, our  
373 findings indicate that pre-pregnancy conditions may partially explain the association  
374 between severe preeclampsia and non-Hispanic Black race/ethnicity. Additionally, data  
375 collected at an initial prenatal care visit has utility for predicting the risk of experiencing  
376 an adverse maternal outcome. Our study findings have important implications for the  
377 preconception care as well as antepartum care of individuals with pre-existing  
378 conditions as adequately assessing a patient's risk is essential to providing risk-  
379 appropriate and equitable care to prevent adverse maternal outcomes.

380

## 381 **Acknowledgments**

382 None.

383

## 384 **Disclosure of Interests**

385 The authors report no disclosures of interest.

386

## 387 **Contribution to Authorship**

388 All authors were involved in the literature search and in the design of the study. MM and  
389 LNS obtained the data and MM performed the data analysis. MM drafted the manuscript  
390 with LNS. KS, MP, and SH revised the manuscript for important intellectual content, and  
391 all authors were involved in the interpretation of the results. All authors approved the  
392 final version to be published.

393

## 394 **Details of Ethics Approval**

395 This study was approved by the Georgia Institute of Technology Internal Review Board  
396 which deemed it exempt from review.

397

398 **Funding**

399 Research reported in this publication was supported in part by Imagine, Innovate and  
400 Impact (I<sup>3</sup>) from the Emory School of Medicine, Georgia Tech, and through the Georgia  
401 CTSA NIH award (UL1-TR002378) and by the National Science Foundation under grant  
402 number DGE-2039655 (Meredith); any opinions, findings, and conclusions or  
403 recommendations expressed in this material are those of the authors and do not  
404 necessarily reflect the views of the National Science Foundation.

## 405 References

- 406 1. *Trends in Maternal Mortality 2000 to 2020, Estimates by WHO, UNICEF, UNFPA, World*  
407 *Bank Group and UNDESA/Population Division.*; 2023.
- 408 2. Pregnancy Mortality Surveillance System | Maternal and Infant Health | CDC. Accessed  
409 May 18, 2022. [https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-](https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm)  
410 [mortality-surveillance-system.htm](https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-system.htm)
- 411 3. Hoyert L. D. *Maternal Mortality Rates in the United States, 2019.*; 2021.  
412 doi:10.15620/CDC:103855
- 413 4. Petersen EE, Davis NL, Goodman D, et al. Racial/Ethnic Disparities in Pregnancy-Related  
414 Deaths — United States, 2007–2016. *MMWR Morb Mortal Wkly Rep.* 2019;68(35):762-  
415 765. doi:10.15585/MMWR.MM6835A3
- 416 5. Liese KL, Mogos M, Abboud S, Decocker K, Koch AR, Geller SE. Racial and Ethnic  
417 Disparities in Severe Maternal Morbidity in the United States. *J Racial Ethn Health*  
418 *Disparities.* 2019;6(4):790-798. doi:10.1007/S40615-019-00577-W
- 419 6. Trost S, Beauregard J, Chandra G, et al. *Pregnancy-Related Deaths: Data from Maternal*  
420 *Mortality Review Committees in 36 US States, 2017-2019.*; 2017.
- 421 7. Geller SE, Rosenberg D, Cox S, Brown M, Simonson L, Kilpatrick S. A scoring system  
422 identified near-miss maternal morbidity during pregnancy. *J Clin Epidemiol.*  
423 2004;57(7):716-720. doi:10.1016/J.JCLINEPI.2004.01.003
- 424 8. Admon LK, Winkelman TNA, Zivin K, Terplan M, Mhyre JM, Dalton VK. Racial and ethnic  
425 disparities in the incidence of severe maternal morbidity in the United States, 2012-2015.  
426 *Obstetrics and Gynecology.* 2018;132(5):1158-1166.  
427 doi:10.1097/AOG.0000000000002937
- 428 9. Stanhope KK, Worrell N, Jamieson DJ, Geary FH, Boulet SL. Double, Triple, and Quadruple  
429 Jeopardy: Entering Pregnancy With Two or More Multimorbid Diagnoses and Increased  
430 Risk of Severe Maternal Morbidity and Postpartum Readmission. *Women's Health Issues.*  
431 Published online July 11, 2022. doi:10.1016/J.WHI.2022.06.005
- 432 10. *Multimorbidity: A Priority for Global Health Research.*; 2018.
- 433 11. Brown HK, McKnight A, Aker A. Association between pre-pregnancy multimorbidity and  
434 adverse maternal outcomes: A systematic review. *Journal of multimorbidity and*  
435 *comorbidity.* 2022;12:26335565221096584. doi:10.1177/26335565221096584
- 436 12. Admon L, Winkelman T, Moniz M, Davis M, Heisler M, Dalton V. Chronic Disease  
437 Prevalence Among Mothers Delivering in the United States, 2004-2013 [38N]. *Obstetrics*  
438 *& Gynecology.* 2017;129(1):S152-S153. doi:10.1097/01.AOG.0000514748.00812.AE
- 439 13. Brown CC, Adams CE, George KE, Moore JE. Associations Between Comorbidities and  
440 Severe Maternal Morbidity. *Obstetrics and gynecology.* 2020;136(5):892-901.  
441 doi:10.1097/AOG.0000000000004057
- 442 14. Easter SR, Bateman BT, Sweeney VH, et al. A comorbidity-based screening tool to predict  
443 severe maternal morbidity at the time of delivery. *Am J Obstet Gynecol.*  
444 2019;221(3):271.e1-271.e10. doi:10.1016/J.AJOG.2019.06.025
- 445 15. Bateman BT, Mhyre JM, Hernandez-Diaz S, et al. Development of a Comorbidity Index for  
446 Use in Obstetric Patients. *Obstetrics and gynecology.* 2013;122(5):957-965.  
447 doi:10.1097/AOG.0B013E3182A603BB



- 448 16. Leonard SA, Kennedy CJ, Carmichael SL, Lyell DJ, Main EK. An Expanded Obstetric  
449 Comorbidity Scoring System for Predicting Severe Maternal Morbidity. *Obstetrics and*  
450 *gynecology*. 2020;136(3):440. doi:10.1097/AOG.0000000000004022
- 451 17. Goretsky A, Dmitrienko A, Tang I, et al. Data Preparation of the nuMoM2b Dataset.  
452 *medRxiv*. Published online August 26, 2021:2021.08.24.21262142.  
453 doi:10.1101/2021.08.24.21262142
- 454 18. Haas DM, Parker CB, Wing DA, et al. A description of the methods of the Nulliparous  
455 Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b). *Am J Obstet*  
456 *Gynecol*. 2015;212(4):539.e1-539.e24. doi:10.1016/J.AJOG.2015.01.019
- 457 19. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure  
458 covariates in survival analysis. *STATISTICS IN MEDICINE Statist Med*. 1998;18:681-694.  
459 doi:10.1002/(SICI)1097-0258(19990330)18:6
- 460 20. Matas JL, Mitchell LE, Sharma S V., Louis JM, Salemi JL. Severe maternal morbidity at  
461 delivery and postpartum readmission in the United States. *Paediatr Perinat Epidemiol*.  
462 2021;35(6):627-634. doi:10.1111/PPE.12762
- 463 21. Dzakpasu S, Deb-Rinker P, Arbour L, et al. Severe maternal morbidity surveillance:  
464 Monitoring pregnant women at high risk for prolonged hospitalisation and death.  
465 *Paediatr Perinat Epidemiol*. 2020;34(4):427. doi:10.1111/PPE.12574
- 466 22. Tang LH, Thygesen LC, Willadsen TG, et al. The association between clusters of chronic  
467 conditions and psychological well-being in younger and older people-A cross-sectional,  
468 population-based study from the Lolland-Falster Health Study, Denmark. *J Comorb*.  
469 2020;10:2235042X20981185. doi:10.1177/2235042X20981185
- 470 23. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal  
471 Mediation Analysis. *J Stat Softw*. 2014;59(5):1-38. doi:10.18637/JSS.V059.I05
- 472 24. Creanga AA, Bateman BT, Kuklina E v., Callaghan WM. Racial and ethnic disparities in  
473 severe maternal morbidity: a multistate analysis, 2008-2010. *Am J Obstet Gynecol*.  
474 2014;210(5):435.e1-435.e8. doi:10.1016/J.AJOG.2013.11.039
- 475 25. Leonard SA, Main EK, Scott KA, Profit J, Carmichael SL. Racial and ethnic disparities in  
476 severe maternal morbidity prevalence and trends. *Ann Epidemiol*. 2019;33:30-36.  
477 doi:10.1016/J.ANNEPIDEM.2019.02.007
- 478 26. Grobman WA, Bailit JL, Rice MM, et al. Racial and Ethnic Disparities in Maternal  
479 Morbidity and Obstetric Care. *Obstetrics and gynecology*. 2015;125(6):1460.  
480 doi:10.1097/AOG.0000000000000735
- 481 27. Prophet J, Kelly K, Domingo J, et al. Severe pre-eclampsia among pregnant women with  
482 sickle cell disease and HIV. *Pregnancy Hypertens*. 2018;11:87-91.  
483 doi:10.1016/J.PREGHY.2018.01.006
- 484 28. Czerwinski S, Gollero J, Qiu C, Sorensen TK, Williams MA. Migraine-Asthma Comorbidity  
485 and Risk of Hypertensive Disorders of Pregnancy. *J Pregnancy*. 2012;2012.  
486 doi:10.1155/2012/858097
- 487 29. Borba VV, Zandman-Goddard G, Shoenfeld Y. Exacerbations of autoimmune diseases  
488 during pregnancy and postpartum. *Best Pract Res Clin Endocrinol Metab*. 2019;33(6).  
489 doi:10.1016/j.beem.2019.101321

- 490 30. Schmidt LJ, Rieger O, Neznansky M, et al. A machine-learning–based algorithm improves  
491 prediction of preeclampsia-associated adverse outcomes. *Am J Obstet Gynecol.*  
492 2022;227(1):77.e1-77.e30. doi:10.1016/j.ajog.2022.01.026
- 493 31. Binder J, Kalafat E, Palmrich P, Pateisky P, Khalil A. Angiogenic markers and their  
494 longitudinal change for predicting adverse outcomes in pregnant women with chronic  
495 hypertension. *Am J Obstet Gynecol.* 2021;225(3):305.e1-305.e14.  
496 doi:10.1016/j.ajog.2021.03.041
- 497 32. Sheen JJ, Wright JD, Goffman D, et al. Maternal age and risk for adverse outcomes. *Am J*  
498 *Obstet Gynecol.* 2018;219(4):390.e1-390.e15. doi:10.1016/j.ajog.2018.08.034
- 499 33. Erickson EN, Carlson NS. Maternal Morbidity Predicted by an Intersectional Social  
500 Determinants of Health Phenotype: A Secondary Analysis of the NuMoM2b Dataset.  
501 *Reprod Sci.* Published online 2022. doi:10.1007/S43032-022-00913-2
- 502 34. Leonard SA, Kennedy CJ, Carmichael SL, Lyell DJ, Main EK. An Expanded Obstetric  
503 Comorbidity Scoring System for Predicting Severe Maternal Morbidity. *Obstetrics and*  
504 *gynecology.* 2020;136(3):440-449. doi:10.1097/AOG.0000000000004022
- 505 35. Minhas AS, Ogunwole SM, Vaught AJ, et al. Racial Disparities in Cardiovascular  
506 Complications with Pregnancy-Induced Hypertension in the United States. *Hypertension.*  
507 2021;78(2):480-488. doi:10.1161/HYPERTENSIONAHA.121.17104
- 508 36. Jean-Francois B, Bailey Lash T, Dagher RK, Green Parker MC, Han SB, Lewis Johnson T.  
509 The Potential for Health Information Technology Tools to Reduce Racial Disparities in  
510 Maternal Morbidity and Mortality. *J Womens Health.* 2021;30(2):274.  
511 doi:10.1089/JWH.2020.8889
- 512 37. Declercq ER, Cabral HJ, Cui X, et al. Using Longitudinally Linked Data to Measure Severe  
513 Maternal Morbidity. *Obstetrics and gynecology.* 2022;139(2):165-171.  
514 doi:10.1097/AOG.0000000000004641

515

516

## Tables

517

Table 1: Descriptive Statistics of the nuMoM2b Study Population by race/ethnicity status (before imputing missing data).

518

BMI, body mass index; Std, standard deviation; HS, high school

	Asian N (%)	Hispanic N (%)	Multiracial N (%)	Non-Hispanic Black N (%)	Non-Hispanic White N (%)	Other N (%)
<b>Total</b>	342 (3.9%)	1487 (17.0%)	348 (4.0%)	1145 (13.1%)	5322 (61.0%)	85 (1.0%)
<b>Education</b>						
Degree work beyond college	158 (46.2%)	148 (10.0%)	56 (16.1%)	73 (6.4%)	1546 (29.1%)	23 (27.1%)
Completed college	110 (32.2%)	249 (16.8%)	68 (19.5%)	117 (10.2%)	1835 (34.5%)	26 (30.6%)
Some college	31 (9.1%)	443 (29.8%)	87 (25.0%)	336 (29.3%)	795 (14.9%)	12 (14.1%)
Assoc/Tech degree	29 (8.5%)	165 (11.1%)	29 (8.3%)	114 (10.0%)	543 (10.2%)	7 (8.2%)
HS grad or GED	9 (2.6%)	271 (18.2%)	47 (13.5%)	291 (25.4%)	391 (7.4%)	10 (11.8%)
Less than HS grad	4 (1.2%)	206 (13.9%)	61 (17.5%)	214 (18.7%)	212 (4.0%)	6 (7.1%)
Missing	1 (0.3%)	5 (0.3%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
<b>Gravidity</b>						
1	262 (76.6%)	1014 (68.2%)	250 (71.8%)	798 (69.7%)	4116 (77.3%)	63 (74.1%)
2	61 (17.8%)	334 (22.5%)	77 (22.1%)	226 (19.7%)	937 (17.6%)	16 (18.8%)
3 +	19 (5.6%)	139 (9.4%)	21 (6.0%)	121 (10.6%)	269 (5.1%)	6 (7.1%)
<b>Insurance</b>						
Government	34 (9.9%)	825 (55.5%)	147 (42.2%)	692 (60.4%)	764 (14.4%)	25 (29.4%)
Commercial	289 (84.5%)	593 (39.9%)	178 (51.2%)	383 (33.5%)	4406 (82.8%)	54 (63.5%)
Self-pay	86 (25.2%)	144 (9.7%)	47 (13.5%)	71 (6.2%)	1130 (21.2%)	15 (17.7%)
Other	8 (2.3%)	31 (2.1%)	11 (3.2%)	34 (3.0%)	87 (1.6%)	2 (2.4%)
<b>Type of Labor</b>						
Spontaneous, not augmented	69 (20.2%)	270 (18.2%)	67 (19.3%)	168 (14.7%)	953 (17.9%)	15 (17.7%)
Spontaneous, augmented	164 (48.0%)	650 (43.7%)	130 (37.4%)	462 (40.4%)	2181 (41.0%)	32 (37.7%)
Induced	81 (23.7%)	475 (31.9%)	131 (37.6%)	463 (40.4%)	1808 (34.0%)	33 (38.8%)
Cesarean w/o labor or induction	28 (8.2%)	91 (6.1%)	20 (5.8%)	51 (4.5%)	379 (7.1%)	5 (5.9%)
<b>Mode of Delivery</b>						
Vaginal	234 (68.4%)	1046 (70.3%)	264 (75.9%)	788 (68.8%)	3923 (73.7%)	55 (64.7%)
Cesarean						
Planned or scheduled	19 (5.6%)	60 (4.0%)	11 (3.2%)	32 (2.8%)	282 (5.3%)	3 (3.5%)
Unscheduled, non-urgent	49 (14.3%)	188 (12.6%)	44 (12.6%)	181 (15.8%)	702 (13.2%)	21 (24.7%)
Unscheduled, urgent	40 (11.7%)	193 (13.0%)	29 (8.3%)	144 (12.6%)	411 (7.7%)	6 (7.1%)
	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std	Mean ± Std
<b>Age</b>	31.0 ± 4.7	24.8 ± 5.52	25.0 ± 6.2	23.3 ± 5.3	28.2 ± 5.2	27.9 ± 5.1
<b>BMI</b>	23.3 ± 4.0	26.7 ± 6.0	27.1 ± 6.9	29.1 ± 8.2	25.8 ± 5.8	27.2 ± 6.3
<b>Percent Federal Poverty</b>	590.9 ± 315.8	293.3 ± 263.2	337.4 ± 295.1	208.0 ± 245.0	488.3 ± 299.8	394.3 ± 287.1
<b>Gestational Age at Delivery (weeks)</b>	38.9 ± 1.9	38.8 ± 2.0	38.6 ± 2.1	38.4 ± 2.5	38.9 ± 2.0	38.4 ± 2.6

519 Table 2: Multilevel Poisson regression with outcome blood transfusion. Bolding indicates statistical significance at 95% confidence.

520 RR, risk ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve

521

	Model 1, crude	Model 2, adjusted	Model 3, condition types RR (95% CI)	Model 4, combined effects
<b>Race</b>				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	<b>1.29 ( 1.06 - 1.57 )</b>	1.20 ( 0.97 - 1.50 )	1.19 ( 0.95 - 1.50 )	1.21 ( 0.96 - 1.52 )
Hispanic	<b>1.28 ( 1.07 - 1.54 )</b>	1.17 ( 0.95 - 1.45 )	1.19 ( 0.96 - 1.48 )	1.19 ( 0.96 - 1.48 )
Multiracial	0.98 ( 0.59 - 1.62 )	0.94 ( 0.57 - 1.52 )	0.86 ( 0.54 - 1.36 )	0.84 ( 0.53 - 1.32 )
Asian	0.86 ( 0.47 - 1.59 )	0.85 ( 0.46 - 1.57 )	0.88 ( 0.48 - 1.63 )	0.88 ( 0.48 - 1.63 )
Other	1.25 ( 0.67 - 2.32 )	1.21 ( 0.66 - 2.22 )	1.17 ( 0.66 - 2.06 )	1.18 ( 0.67 - 2.09 )
<b>Confounders</b>				
<b>Pre-Pregnancy Conditions</b>				
Cardiovascular			1.11 ( 0.88 - 1.39 )	1.17 ( 0.92 - 1.48 )
Endocrine			1.25 ( 1.00 - 1.56 )	<b>1.28 ( 1.02 - 1.60 )</b>
Kidney			1.28 ( 0.93 - 1.75 )	1.27 ( 0.93 - 1.75 )
Hematologic			<b>1.42 ( 1.23 - 1.64 )</b>	<b>1.42 ( 1.23 - 1.64 )</b>
Autoimmune			<b>1.36 ( 1.04 - 1.78 )</b>	<b>1.36 ( 1.04 - 1.79 )</b>
Gynecological			0.69 ( 0.48 - 1.00 )	0.73 ( 0.50 - 1.06 )
<b>Combined effects</b>				
Cardiovascular: Endocrine				0.83 ( 0.38 - 1.83 )
Cardiovascular: Gynecological				0.67 ( 0.22 - 2.02 )
Overall AUC	0.56	0.55	0.59	0.59

522

523 Table 3: Multilevel Poisson regression with outcome postpartum readmission. Bolding indicates statistical significance at 95% confidence.

524 RR, risk ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve


	Model 1, crude	Model 2, adjusted	Model 3, condition types RR (95% CI)	Model 4, combined effects
<b>Race</b>				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	1.17 ( 0.95 - 1.45 )	0.96 ( 0.75 - 1.21 )	0.97 ( 0.76 - 1.24 )	1.01 ( 0.79 - 1.29 )
Hispanic	1.18 ( 0.98 - 1.43 )	1.05 ( 0.85 - 1.28 )	1.08 ( 0.89 - 1.31 )	1.07 ( 0.88 - 1.30 )
Multiracial	1.20 ( 0.87 - 1.66 )	1.10 ( 0.79 - 1.53 )	1.04 ( 0.73 - 1.48 )	1.01 ( 0.70 - 1.46 )
Asian	0.30 ( 0.05 - 1.61 )	0.32 ( 0.06 - 1.71 )	0.29 ( 0.07 - 1.16 )	0.29 ( 0.08 - 1.05 )
Other	1.42 ( 0.96 - 2.11 )	1.36 ( 0.90 - 2.04 )	1.42 ( 0.94 - 2.16 )	1.43 ( 0.95 - 2.15 )
<b>Confounders</b>				
<b>Pre-Pregnancy Conditions</b>				
Cardiovascular			1.20 ( 1.00 - 1.45 )	<b>1.33 ( 1.04 - 1.68 )</b>
Lung			1.10 ( 0.90 - 1.34 )	1.26 ( 0.99 - 1.61 )
Endocrine			1.19 ( 0.97 - 1.45 )	<b>1.33 ( 1.03 - 1.71 )</b>
Hematologic			1.14 ( 0.94 - 1.39 )	<b>1.32 ( 1.02 - 1.71 )</b>
Autoimmune			<b>1.55 ( 1.22 - 1.97 )</b>	<b>1.52 ( 1.19 - 1.94 )</b>
Neurological			1.09 ( 0.90 - 1.32 )	1.25 ( 0.99 - 1.58 )
Mental			0.97 ( 0.80 - 1.19 )	1.06 ( 0.85 - 1.31 )
<b>Combined effects</b>				
Cardiovascular: Neurological				0.84 ( 0.57 - 1.25 )
Cardiovascular: Endocrine				0.76 ( 0.52 - 1.11 )
Cardiovascular: Hematologic				0.89 ( 0.61 - 1.32 )
Lung: Neurological				0.73 ( 0.43 - 1.23 )
Lung: Endocrine				0.80 ( 0.48 - 1.33 )
Lung: Hematologic				0.84 ( 0.51 - 1.40 )
Neurological: Mental				0.79 ( 0.50 - 1.27 )
Endocrine: Hematologic				0.82 ( 0.47 - 1.43 )
Hematologic: Gynecological				0.38 ( 0.13 - 1.18 )
Overall AUC	0.54	0.58	0.58	0.57

525 Table 4: Multilevel Poisson regression with outcome severe preeclampsia, bolding indicates statistical significance at 95% confidence

526 RR, risk ratio; CI, confidence interval; AUC, area under the receiver operating characteristic curve

	Model 1, crude	Model 2, adjusted	Model 3, condition types	Model 4, combined effects
	RR (95% CI)			
(Intercept)	<b>0.45 ( 0.41 - 0.49 )</b>	<b>0.23 ( 0.16 - 0.33 )</b>	<b>0.23 ( 0.16 - 0.34 )</b>	<b>0.23 ( 0.16 - 0.34 )</b>
Race				
Non-Hispanic White (reference)	1.00	1.00	1.00	1.00
Non-Hispanic Black	<b>1.45 ( 1.29 - 1.63 )</b>	<b>1.22 ( 1.06 - 1.41 )</b>	1.15 ( 0.99 - 1.34 )	1.16 ( 0.99 - 1.35 )
Hispanic	1.09 ( 0.92 - 1.28 )	1.04 ( 0.87 - 1.23 )	0.97 ( 0.82 - 1.14 )	0.97 ( 0.82 - 1.15 )
Multiracial	<b>1.28 ( 1.02 - 1.60 )</b>	1.09 ( 0.88 - 1.35 )	1.06 ( 0.85 - 1.32 )	1.06 ( 0.85 - 1.31 )
Asian	0.93 ( 0.62 - 1.37 )	0.98 ( 0.67 - 1.43 )	0.96 ( 0.67 - 1.38 )	0.97 ( 0.67 - 1.38 )
Other	1.26 ( 0.81 - 1.96 )	1.20 ( 0.78 - 1.86 )	1.21 ( 0.76 - 1.91 )	1.21 ( 0.77 - 1.91 )
Confounders				
Pre-Pregnancy Conditions				
Cardiovascular			<b>1.77 ( 1.61 - 1.96 )</b>	<b>1.71 ( 1.54 - 1.89 )</b>
Kidney			<b>1.27 ( 1.03 - 1.56 )</b>	<b>1.25 ( 1.01 - 1.53 )</b>
Hematologic			0.90 ( 0.77 - 1.04 )	0.80 ( 0.59 - 1.08 )
Gastrointestinal			0.71 ( 0.48 - 1.05 )	0.70 ( 0.47 - 1.05 )
Gynecological			0.84 ( 0.70 - 1.02 )	0.85 ( 0.71 - 1.02 )
Combined effects				
Cardiovascular: Hematologic				1.26 ( 0.91 - 1.75 )
Overall AUC	0.56	0.61	0.65	0.65

527



All Participants with Data on Pregnancy Outcomes  
N = 9289

N = 8929

N = 8909

N = 8765

N = 8736

N = 8733

N = 8729

Excluded Pregnancy Outcomes (Fetal Demise, Elective Termination, Indicated Termination, Don't Know, Refused)  
N = 360

Gestational Age (< 22) or (> 43)  
N = 20

Labor, Delivery, and Postpartum (CMA) Form Not Completed  
N = 144

Across Visits Conditions and Medications (VXX) Form Not Completed  
N = 29

Race Missing  
N = 3

Mode of Delivery Missing  
N = 4